Neoral conversion from Sandimmune in maintenance renal transplant patients: an individualized approach.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Journal of the American Society of Nephrology

• Publication date

  1998-07-01

• Fields of study

  Medicine

• Identifiers
  PMID 9644641
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Improved absorption of cyclosporin A from a new microemulsion formulation: implications for dosage and monitoring

  2004cited by this paper
• Safety and tolerability of neoral vs sandimmune: 1-year data in primary renal allograft recipients

  1996cited by this paper
• Safety and tolerability of CyA microemulsion formulation (Sandimmun Neoral) in stable renal transplant patients after 24 months of treatment. German Neoral Study Group.

  1996cited by this paper
• Long‐term outcome after switch from cyclosporine‐based triple‐drug immunosuppression to double therapy at three months

  1996cited by this paper
• Cyclosporine bioavailability: dosing implications and impact on clinical outcomes in select transplantation subpopulations *

  1996cited by this paper
• UK multicentre study to assess the safety and tolerability of Neoral in stable renal transplant patients. UK Neoral Study Group.

  1996cited by this paper
• Conversion from conventional Sandimmun to Neoral therapy in stable renal transplant recipients.

  1996cited by this paper
• A randomized, controlled trial to assess the safety of switching stable renal transplant patients from Sandimmun to Sandimmun Neoral.

  1996cited by this paper
• Safety and tolerability of Neoral vs Sandimmune: 1-year data in primary renal allograft recipients. Neoral Study Group.

  1996cited by this paper
• UK multicentre study to assess the safety and tolerability of Neoral in stable renal transplant patients

  1996cited by this paper
• Conversion from Sandimmune to Neoral and induction therapy with Neoral in pediatric renal transplant recipients.

  1996cited by this paper
• Safety, tolerability, and pharmacokinetics of Sandimmun Neoral: conversion study in stable renal transplant recipients.

  1996cited by this paper
• Conversion from Sandimmune to Neoral in stable renal and pancreas transplant recipients enhances cyclosporine absorption.

  1996cited by this paper
• The nephrotoxicity of immunosuppressive drugs.

  1995cited by this paper
• Consistent absorption of cyclosporine from a microemulsion formulation assessed in stable renal transplant recipients over a one-year study period.

  1995cited by this paper
• Clinical experience transferring kidney transplant patients from Sandimmun to Sandimmun Neoral--results after 3 months.

  1995cited by this paper
• Long-term efficacy and safety of cyclosporine in renal-transplant recipients.

  1994cited by this paper
• CYCLOSPORINE PHARMACOKINETICS AND VARIABILITY FROM A MICROEMULSION FORMULATION—A MULTICENTER INVESTIGATION IN KIDNEY TRANSPLANT PATIENTS

  1994cited by this paper
• Conversion from Sandimmun to Sandimmun Neoral in patients with stable renal allografts: results after 1 month.

  1994cited by this paper
• Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients--a concentration-controlled comparison with the commercial formulation.

  1994cited by this paper
• Optimal combination of immunosuppressive agents for renal transplantation: first report of a multicentre, randomised trial comparing cyclosporine+prednisolone with cyclosporine+azathioprine and with triple therapy in cadaver renal transplantation. The Australian Collaborative Trials Committee.

  1993cited by this paper
• Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: Racial differences in bioavailability

  1992cited by this paper
• Benefits of quadruple immunosuppressive therapy in recipients of living related donor kidneys. A review of 855 operations.

  1992cited by this paper
• A RANDOMIZED TRIAL COMPARING DOUBLE‐DRUG AND TRIPLE‐DRUG THERAPY IN PRIMARY CADAVERIC RENAL TRANSPLANTS

  1990cited by this paper
• Long-term use of cyclosporin in liver grafting.

  1985cited by this paper
• Improved immunosuppression for heart transplantation.

  1985cited by this paper
• Clinical experience with cyclosporine and azathioprine at Brigham and Women's Hospital.

  1985cited by this paper

• Antimicrobial Peptides and Nanotechnology, Recent Advances and Challenges

  2018cites this paper
• CyclosporinReview of the Pharmacokinetic Properties, Clinical Efficacy and Tolerability of a Microemulsion-Based Formulation (Neoral ® ) 1 in Organ Transplantation

  2016cites this paper
• Disruptions in the Supply of Medications Used in Transplantation: Implications and Management Strategies for the Transplant Clinician

  2013cites this paper
• Change of Cyclosporine Absorption over the Time after Kidney Transplantation

  2012cites this paper
• Nephro-Urology Monthly Nephro-Urology Monthly Nephro-Urology Monthly

  2012cites this paper
• Cyclosporin

  2012cites this paper
• Drug‐Drug Interaction After Single Oral Doses of the Furanocoumarin Methoxsalen and Cyclosporine

  2006cites this paper
• Evaluation of performance factors affecting two formulations of cyclosporine in pediatric renal transplant patients.

  2006cites this paper
• The impact of cyclosporine on the development of immunosuppressive therapy--pediatric transplantation using cyclosporine.

  2004cites this paper
• Cyclosporine monitoring in pediatric allograft recipients – time for a change!

  2004cites this paper
• Conversion of stable renal allograft recipients to a bioequivalent cyclosporine formulation

  2002cites this paper
• Impact of cyclosporine dosing frequency on graft function and survival after the conversion from sandimmun to neoral in stable kidney transplanted patients.

  2002cites this paper
• Calcineurin inhibitors and chronic renal allograft dysfunction: Not enough or too much?

  2001cites this paper
• Maintenance immunosuppression in the renal transplant recipient: an overview.

  2001cites this paper
• Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation.

  2001cites this paper
• Risk factors of cyclosporine nephrotoxicity after conversion from Sandimmune to Neoral.

  2001cites this paper
• Recommendations for bioequivalence testing of cyclosporine generics revisited.

  2000cites this paper
• Renal transplantation in black Americans.

  2000cites this paper
• Safety of Neoral conversion in maintenance renal transplant patients: A one-year, double-blind study. NOVARTIS OLN-353 Study Group.

  1999cites this paper
• Nine-month follow-up of SangCya (Sang-35) in kidney transplant patients after conversion from Sandimmune.

  1999cites this paper
• Cyclosporin Microemulsion (Neoral®)†

  1998cites this paper
• Cyclosporin Microemulsion (Neoral ® ) † A Pharmacoeconomic Review of its Use Compared with Standard Cyclosporin in Renal and Hepatic Transplantation

  1998cites this paper
• Cyclosporin microemulsion (Neoral). A pharmacoeconomic review of its use compared with standard cyclosporin in renal and hepatic transplantation.

  1998cites this paper